Last reviewed · How we verify
Heparin anticoagulation
Heparin anticoagulation is a Anticoagulant Small molecule drug developed by University Medical Centre Ljubljana. It is currently FDA-approved for Prevention and treatment of venous thromboembolism, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Heparin anticoagulation is used to treat conditions such as blood clots, thrombosis, and cerebral venous thrombosis, as well as in patients with end-stage renal disease undergoing kidney replacement therapy. It works by activating Antithrombin-III, a protein that inhibits blood clot formation, through its oligosaccharide modality.
At a glance
| Generic name | Heparin anticoagulation |
|---|---|
| Sponsor | University Medical Centre Ljubljana |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically increases its ability to inhibit thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing thrombi. Heparin is used for both treatment and prevention of thrombotic events.
Approved indications
- Prevention and treatment of venous thromboembolism
- Acute coronary syndrome
- Atrial fibrillation with thromboembolism risk
- Prevention of clotting during hemodialysis and extracorporeal circulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
- Hyperkalemia
Key clinical trials
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Dose for Reversal of Heparin After Cardiopulmonary Bypass (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin anticoagulation CI brief — competitive landscape report
- Heparin anticoagulation updates RSS · CI watch RSS
- University Medical Centre Ljubljana portfolio CI
Frequently asked questions about Heparin anticoagulation
What is Heparin anticoagulation?
How does Heparin anticoagulation work?
What is Heparin anticoagulation used for?
Who makes Heparin anticoagulation?
What drug class is Heparin anticoagulation in?
What development phase is Heparin anticoagulation in?
What are the side effects of Heparin anticoagulation?
What does Heparin anticoagulation target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets)
- Manufacturer: University Medical Centre Ljubljana — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention and treatment of venous thromboembolism
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Atrial fibrillation with thromboembolism risk
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing